載入中
NASDAQHealthcareBiotechnology
最新資料
US$4.36
+US$0.41 · +10.38%
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
前收盤價
US$4.36
+US$0.41 · +10.38%
盤中時間採用ET。市場資料可能有所延遲。
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
日內區間
目前US$4.36
52週區間
目前US$4.36
盤中時間採用ET。市場資料可能有所延遲。
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
日內區間
目前US$4.36
52週區間
目前US$4.36
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7468.1萬 USD | 5883.9萬 USD | 4387.6萬 USD | 3968.1萬 USD | 1000萬 USD |
| 銷貨成本 | 1.21億 USD | 4523.8萬 USD | 4258.7萬 USD | 4827.5萬 USD | — |
| 毛利 | −4627.3萬 USD | 1360.1萬 USD | 128.9萬 USD | −859.4萬 USD | 1000萬 USD |
| 研究與開發 | 4.25億 USD | 3.14億 USD | 2.41億 USD | 1.56億 USD | 1.35億 USD |
| 銷售、一般及管理費用 | 1.77億 USD | 1.78億 USD | 1.11億 USD | 8159.9萬 USD | 5768.2萬 USD |
| 營業費用 | 6.02億 USD | 4.93億 USD | 3.51億 USD | 2.37億 USD | 1.93億 USD |
| 利息收入 | 2278.8萬 USD | 1575.8萬 USD | 1911.6萬 USD | 625.4萬 USD | 7.3萬 USD |
| 利息支出 | 181萬 USD | 157.2萬 USD | 9.7萬 USD | 5.5萬 USD | 295.2萬 USD |
| 折舊和攤銷 | 8370.1萬 USD | 3649.4萬 USD | 2440.2萬 USD | 1175.6萬 USD | 840.5萬 USD |
| 營業利益 | −6.48億 USD | −4.79億 USD | −3.5億 USD | −2.46億 USD | −1.83億 USD |
| 淨利 | −6.45億 USD | −4.64億 USD | −3.28億 USD | −2.39億 USD | −1.86億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.30
上漲空間 21.56%報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK8722.7萬1.27%55.62億 USD0.75%US$89.62+2.31%
State Street SPDR S&P Biotech ETFXBI6649.93萬0.67%98.74億 USD0.35%US$153.77+3.00%
ARK Genomic Revolution ETFARKG5817.27萬2.84%15.57億 USD0.75%US$51.30+4.08%
Vanguard Morningstar Total Stock Market ETFVTI5404.89萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM5349.14萬0.07%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB3897.36萬0.02%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK2232.72萬0.05%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF2071.17萬0.02%954億 USD0.05%US$235+0.80%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
